SVCM
Saturn V Capital Management Portfolio holdings
AUM
$247M
This Quarter Return
+40.7%
1 Year Return
+2.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$261M
AUM Growth
+$261M
(+9.3%)
Cap. Flow
-$28.1M
Cap. Flow
% of AUM
-10.75%
Top 10 Holdings %
Top 10 Hldgs %
74.44%
Holding
26
New
6
Increased
7
Reduced
10
Closed
3
Top Buys
| 1 |
argenx
ARGX
|
$15.6M |
| 2 |
Merus
MRUS
|
$9.6M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$8.56M |
| 4 |
Disc Medicine
IRON
|
$3.74M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
$3.14M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$14.4M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$12.8M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
$12.1M |
| 4 |
CBAY
Cymabay Therapeutics
CBAY
|
$8.84M |
| 5 |
Biogen
BIIB
|
$8.33M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cytokinetics
CYTK
$4.23B
| $37.4M | 14.32% |
448,144
-47,024
| -9% | -$3.93M |
|
|
2
Crinetics Pharmaceuticals
CRNX
$2.92B
| $28M | 10.72% |
787,132
-339,447
| -30% | -$12.1M |
|
3
KalVista Pharmaceuticals
KALV
$678M
| $22.1M | 8.48% |
1,807,563
-2,683
| -0.1% | -$32.9K |
|
|
4
argenx
ARGX
$43.6B
| $19.5M | 7.45% |
51,175
+41,101
| +408% | +$15.6M |
|
|
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
| $17.7M | 6.78% |
750,250
-374,209
| -33% | -$8.84M |
|
6
Ascendis Pharma
ASND
$11.8B
| $16.6M | 6.35% |
131,759
+19,286
| +17% | +$2.43M |
|
|
7
Amylyx Pharmaceuticals
AMLX
$836M
| $16.2M | 6.19% |
1,099,268
+213,125
| +24% | +$3.14M |
|
8
AnaptysBio
ANAB
$569M
| $14.2M | 5.45% |
664,276
+87,175
| +15% | +$1.87M |
|
9
BioMarin Pharmaceuticals
BMRN
$11.2B
| $11.5M | 4.4% |
119,188
+9,503
| +9% | +$916K |
|
10
Syndax Pharmaceuticals
SNDX
$1.41B
| $11.2M | 4.29% |
518,799
-289,170
| -36% | -$6.25M |
|
|
11
Merus
MRUS
$4.98B
| $10.7M | 4.1% |
389,333
+349,267
| +872% | +$9.6M |
|
12
iTeos Therapeutics
ITOS
| $9.07M | 3.47% |
828,232
-166,524
| -17% | -$1.82M |
|
|
13
Apellis Pharmaceuticals
APLS
$3.48B
| $8.56M | 3.27% |
+142,927
| New | +$8.56M |
|
|
14
Biogen
BIIB
$19.4B
| $8.4M | 3.22% |
32,469
-32,207
| -50% | -$8.33M |
|
15
Astria Therapeutics
ATXS
$349M
| $7.61M | 2.91% |
990,663
-228,430
| -19% | -$1.75M |
|
|
MORF
16
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $6.13M | 2.35% |
212,343
+75,600
| +55% | +$2.18M |
|
17
Cogent Biosciences
COGT
$1.69B
| $4.45M | 1.7% |
756,681
-1,018,734
| -57% | -$5.99M |
|
|
18
Disc Medicine
IRON
$2.07B
| $3.74M | 1.43% |
+64,784
| New | +$3.74M |
|
19
Amicus Therapeutics
FOLD
$2.34B
| $2.84M | 1.09% |
+199,973
| New | +$2.84M |
|
20
Alnylam Pharmaceuticals
ALNY
$58.5B
| $1.98M | 0.76% |
+10,327
| New | +$1.98M |
|
21
Phathom Pharmaceuticals
PHAT
$864M
| $1.46M | 0.56% |
+160,075
| New | +$1.46M |
|
22
Jasper Therapeutics
JSPR
$45.5M
| $1.09M | 0.42% |
1,386,215
-800
| -0.1% | -$631 |
|
|
AMAM
23
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $752K | 0.29% |
+52,781
| New | +$752K |
|
24
BioCryst Pharmaceuticals
BCRX
$1.74B
| – | – |
-982,458
| Closed | -$6.96M |
|
|
25
Sarepta Therapeutics
SRPT
$1.78B
| – | – |
-118,401
| Closed | -$14.4M |
|